The human ABCB1 protein, (P-glycoprotein or MDR1) is a membrane-bound glycoprotein that harnesses the energy of ATP hydrolysis to drive the unidirectional transport of substrates from the cytoplasm to the extracellular space. As a large range of therapeutic agents are known substrates of ABCB1 protein, its role in the onset of multidrug resistance has been the focus of much research. This role has been of particular interest in the field of pharmacogenomics where genetic variation within the ABCB1 gene, particularly in the form of single nucleotide polymorphisms (SNPs), is believed to contribute to inter-individual variation in ABCB1 function and drug response. In this review we provide an update on the influence of coding region SNPs within the ABCB1 gene on drug pharmacokinetics. By utilizing the crystal structure of the mouse ABCB1 homolog (Abcb1a), which is 87% homologous to the human sequence, we accompany this discussion with a graphical representation of residue location for amino acids corresponding to human ABCB1 coding region SNPs. Also, an assessment of residue conservation, which is calculated following multiple sequence alignment of 11 confirmed sequences of ABCB1 homologs, is presented and discussed. Superimposing a 'heat map' of residue homology to the Abcb1a crystal structure has permitted additional insights into both the conservation of individual residues and the conservation of their immediate surroundings. Such graphical representation of residue location and conservation supplements this update of ABCB1 pharmacogenetics to help clarify the often confounding reports on the influence of ABCB1 polymorphisms on drug pharmacokinetics and response.
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Keywords: ABCB1; P-glycoprotein; MDR1; SNP; drug transporter; drug resistance ABCB1 is involved in multidrug resistance and altered drug pharmacokinetics ABCB1 (P-glycoprotein or P-gp/MDR1) is a member of the ATP-binding cassette superfamily of proteins and is responsible for the unidirectional efflux of substrates across cellular membranes. 1 It has been widely associated with multidrug resistance (MDR) during the treatment of various diseases, including cancer, epilepsy, heart disease and AIDS. 2, 3 The MDR phenotype may manifest itself through differences in drug efficacy or through more subtle effects such as the onset of adverse side effects and altered drugdrug interactions. 4, 5 It is important to note early that the role of ABCB1 in drug resistance and pharmacokinetics is often complicated by additional factors that may affect the proteins expression or location. Drug pharmacokinetics may be altered for example following the activation of the transcription factor pregnane-X-receptor (PXR) and the subsequent upregulation of ABCB1. 6 In this case, various small molecules activate PXR causing it to form a heterodimer with the retinoid X receptor-a , which subsequently binds to response elements within the ABCB1 promoter region. Small molecules that activate PXR may not necessarily be substrates of ABCB1 themselves and it is through this mechanism that drugs administered simultaneously with ABCB1 substrates, may exacerbate the effect of ABCB1 on drug resistance. Evidence also suggests that ABC proteins, if not ABCB1 itself, localize to the lipid bilayers of intracellular vesicles where they facilitate the uptake of drug into lysosomes or endosomes for further processing. 7, 8 Cross specificity of substrates with alternative drug transporters is particularly important where these alternative transporters directly influence the intracellular concentrations of ABCB1 substrates.
Although there is a wide consensus on the marginal effect of genetic variants to the plasma pharmacokinetics of drugs, varying degrees of evidence exist on the effect of drug transporter polymorphisms on intracellular or cerebrospinal fluid changes on drugs concentration. 9 Moreover, the contribution of ABCB1 to multidrug resistance is well established and this has been attributed to its overall structure and function, which has been studied extensively 1, 10 since its discovery in 1976 11 to the crystallization of the first mammalian homolog, the mouse ABCB1 homolog Abcb1a. 12 It is well known that substrates of ABCB1 have a wide range of structural and chemical diversity. These diverse small molecule substrates have been proposed to bind to residues located on the internal surface of the substrate-binding region, which is essentially a large open cavity composed of 12 transmembrane domains that span the lipid bilayer. 1, 12 Connected to these transmembrane domains are cytoplasmic nucleotide-binding domains (NBDs) where ATP binding and hydrolysis occurs, 13, 14 facilitated by several highly conserved motifs [15] [16] [17] [18] including the Walker A, Walker B, Signature C motif, A-loop, D-loop, H-loop and Q-loop. These motifs are common to most ABCB1 homologs and alternative members of the ABC superfamily alike and it has been proposed that each contributes to an ATP-binding pocket that forms during NBD dimerization. 19 Substrate dissociation and efflux result from conformational changes in the protein that occurs upon ATP binding. 19, 20 With ABCB1 actively transporting such a wide range of substrates, 18 the consequences of amino acid substitution, or altered mRNA production/processing via genetic polymorphisms may be significant. This is particularly true where alterations to substrate-binding sites or highly conserved regions of the NBD potentially impact protein function and the efflux or pharmacokinetics of small molecules.
Single nucleotide polymorphisms (SNPs) in the ABCB1 gene may contribute to inter-individual differences in drug response
In recent years, great interest has been generated with regards to the influence of genetic variation at the ABCB1 gene on the expression and function of the protein.
The most common form of genetic variation is the SNP and, depending on the location of the SNP in the gene, the mechanism by which their influence is exerted will differ. SNPs located in the intronic or untranslated regions of the gene may alter mRNA generation, integrity or processing. Those located in the coding regions, however, may alter protein structure directly, producing amino-acid substitutions (non-synonymous SNPs) or altering the mRNA sequence, and possibly its structure and stability, while encoding the same amino acid (synonymous SNPs). The mechanisms driving SNP inheritance have been reviewed previously, specifically in relation to the ABC transport proteins.
21,22
The influence of SNPs may be manifested through the onset of adverse side effects, altered drug efficacy or multidrug resistance profile. The role of ABCB1 in drug resistance as well as its contribution to inter-individual differences in drug response has received a growing amount of attention over the past decade leading to a number of comprehensive reviews on the topic. 3, 9, 18, 23 Despite this, with the recent crystallization of the mammalian ABCB1, 12 the discovery of additional SNPs at the ABCB1 locus and a substantial increase in the number of association studies involving ABCB1, an update on role of ABCB1 polymorphisms in the pharmacokinetics of drugs is warranted. By exploiting the high resolution mammalian Abcb1a crystal structure, we are now able to map coding region SNPs to their corresponding positions within the 3D structure, providing greater insight into their respective locations and relationships with both conserved regions, and neighboring residues, which may also correspond to coding region SNPs. Hence in this review, in addition to an update on ABCB1 pharmacogenetic association studies, insights from 3D modeling into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics are also discussed. A flash movie showing the corresponding location on the 3D structure of the various SNPs associated with functional differences is also provided (http://pfs.nus.edu.sg/demo_src/ abcb1.html). A detailed explanation on the methods of homology calculation and the tertiary location of SNPs based on the mouse Abcb1a protein crystal structure is included as Supplementary Material.
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ABCB1 is polymorphic and has been well conserved during evolution
The human ABCB1 protein sequence is 87% identical to the M. musculus homolog Abcb1a (Supplementary Figure 1) . Eleven confirmed ABCB1 homologs from different organisms are available on NCBI's Homologene resource (Supplementary Table 1 ). Multiple sequence alignment using the ClustalW program 24, 25 (accessible at http://www.ebi.ac.uk/ Tools/msa/clustalw2/) highlights that the MDR1 protein sequence is reasonably well conserved from E. coli to humans, although it is only a half transporter in the lower organisms (Sav1866 and MsbA) (Figure 1 ). In this manuscript, SNP nomenclature begins with the prefix 'E', which indicates the exon location of the polymorphism, in the ABCB1 gene. A total of 66 coding SNPs, including 24 synonymous (sSNPs-prefix 's' in the Figures and Table) and 42 non-synonymous (nsSNPs-prefix 'ns' in the Figures and Table) SNPs, at the human ABCB1 locus were found in the latest dbSNP database (Build 131) ( Table 1 and Supplementary   Table 2 ). All residues corresponding to sSNPs in ABCB1 are conserved between human and mouse (shaded blue in Table  1 , Figure 1 ) whereas five residues (R442, L554, T558, S565 and I598; #s8, #s11, #s12, #13 and #s14 respectively in Figure 2c ) are conserved in all 11 organisms examined ( Table 1) . Of the 42 nsSNPs, 37 (88.1%) can be mapped to the M. musculus crystal structure based on a pair-wise alignment method using ClustalW algorithm (Table 1 , Supplementary Figure 1) . 24, 25 The major amino-acid alleles of 31 of the 37 nsSNPs (83.7%) are conserved between human and mouse (Table 1, Figure 1 ). Of these, just two residues (E566, and D1088; #ns10 and #ns28 in Figure 2b respectively) are conserved in all 11 organisms examined, whereas 12 are conserved in at least 7 of the 11 organisms examined ( Table 1 ). The global view of SNP architecture at the ABCB1 locus reveals that the majority of the amino acid substitution sites lie within the NBDs, close to the highly conserved Walker A and Walker B motifs as well as in close proximity to the ABC signature motif C (Figure 1, Figures 2b  and c) . It is observed that the NBDs have B6.2 SNPs per 100 Figure 1 Homology map derived from the multiple sequence alignment of 11 ABCB1 homologs. Black bar height indicates the number of identical residues between the 11 homologous sequences at the respective amino-acid site (between 11 and 0 identical residues may occur). The synonymous single nucleotide polymorphism and non-synonymous single nucleotide polymorphism (sSNPs and nsSNPs) whose corresponding residues can be mapped into the mouse protein are represented with blue and red dots, respectively. The C-terminal portion of the alignment where the bacterial half transporter sequences of Sav1866 and MsbA were repeated to produce a full sequence is marked with an arrow. This map also depicts the putative P-glycoprotein secondary structure shown in a linear chain format modified from the Protein Database (PDB). Conserved regions essential for protein function are highlighted both in the alignment and Abcb1a crystal structure.
amino acids whereas the transmembrane domains have only B3.7 SNPs per 100 amino acids. In fact, one ns-SNP (E26/ 3222A4C (C1074W), ns#27 in Figure 2b ) lies within the Walker A motif of the C-NBD itself (Table 1, Figure 1 ). Of the 14 amino-acid substitution sites located outside of the NBDs five are located on the external surface of the protein and three on the internal surface of the substrate-binding cavity (Figure 2 ).
Review of SNPs associated with protein function or expression
Two sSNPs and 12 nsSNPs have been associated with differences in function or expression of the ABCB1 protein (Supplementary Table 2 ). Four of the 12 associated nsSNPs (E3/61A4G, E5/266C4T, E17/1985T4C and E17/2005C4T) cannot be mapped to the mouse crystal Table 1 Genetic conservation of amino acids corresponding to ABCB1 coding region SNPs 
E18/2207T>A (I736K)  TM7  I736  I737  V732  I745  M779  I771  V682  I820  I37  L48  V814  72.7  36.7  38 ns16 rs77144566  E19/2281A>C  (A761S)  TM8  A761  V763  I757  A769  V802  I796  G706  I844  I647  G655  L836 The conservation of residues corresponding to all coding regions SNPs was obtained following multiple sequence alignment of 11 confirmed ABCB1 homolog protein sequences. For each species the amino acid, as well as its position in the corresponding sequence, is indicated. Please refer to the Supplementary Materials for a description of the regional conservation score. SNPs of particular pharmacogenetic interest are marked in bold and flanked by the same color that corresponds to the SNP ID in Figures 2-4 . Highlighted in faded blue are the rows containing synonymous SNPs. Shaded in green is the sequence alignment obtained after re-using the same bacterial half-transporter sequence that were used for the first half of the alignment. The SNP nomenclature (that is #ns or #s) is similar to what were used throughout this article.
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The residues corresponding to SNPs E13/1236C4T, E22/2677G4T/A and E27/3435C4T are varied in their evolutionary conservation and located in distant regions of the protein Of the 14 SNPs associated with drug response or pharmacokinetics, three in particular have been researched extensively. [26] [27] [28] [29] [30] [31] At the DNA level, these three SNPs are regularly identified to be in high linkage disequilibrium 29 and are present at highly variable frequencies in different populations (Supplementary Table 2 ). Two of these SNPs are synonymous (E13/1236C4T (#s6 in Figure 2c ) and E27/ 3435C4T (#s20 in Figure 2c) ) whereas E22/2677G4T/A (#ns22 in Figure 2b ) is a non-synonymous triallelic polymorphism that confers a Ser to Ala/Thr amino-acid substitution at residue position 893. When mapped to the crystal structure of Abcb1a, both synonymous SNPs are found to lie in different regions of the protein (Figure 2c ; see flash movie at http://pfs.nus.edu.sg/demo_src/abcb1.html), located more than 50 Å of each other and have very different levels of conservation.
A full description of regional conservation score calculation is presented in the Supplementary Material and in Table 1 . Briefly, a list of amino acids located within 10 Å of the residue in question was obtained from the crystal structure of Abcb1a. The individual conservation scores of each residue in the list, as well as five residues on either side of these amino acids (based on the mRNA sequence), was averaged and assigned to the corresponding residue as the regional conservation score (Table 1) . With this five aminoacids method, we were able to obtain a finer spread of data and demarcate the regions with strong difference in conservation scores as compared with using more residues in the calculation.
SNP E13/1236C4T (#s6 in Figure 2c ) correlates to a glycine residue located on the external surface of the Nterminal NBD (Figures 1 and 2c) . It lies within a b-sheet and is located between the functional A-loop (10 amino acids away) and the Walker A motif (15 amino acids away). Importantly, this polymorphism has an individual conservation score of only 28% suggesting that variation in residue properties have been tolerated during the evolution of the protein (Table 1, Figure 3a ). Other residues found at this position in homologous structures include lysine, aspartic acid and asparagine (Table 1) . Each residue differs from glycine in their polarity and side chain charge and all three are more hydrophilic (À3.5 to À3.9 versus À0.4). This tolerance of variation is important given any effect from E13/1236C4T is likely to be exerted at the mRNA level.
The other synonymous SNP, E27/3435C4T (I1145) (#s20 in Figure 2c ), is highly conserved (73%) across the 11 confirmed sequences of ABCB1 homologs (Table 1, Figure 2 (a) A global view of residue conservation following the multiple sequence alignment of 11 ABCB1 homologs using the ClustalW algorithim (see Supplementary Table 1 and Table 1 ). A heat map with differing colors depending on the residue conservation score is shown (blue: low conservation, red: high conservation). (b) Global view of amino-acid residues corresponding to non-synonymous single nucleotide polymorphisms (SNPs) (prefixed as 'ns') and (c) synonymous SNPs (prefixed as 's') within the human ABCB1 gene mapped to the mouse Abcb1a crystal structure (PDB: 3G5U). Identical residues between human and mouse are represented as blue (sSNPs) and red (nsSNPs) balls/fonts. Those residues that are not homologous are represented as green balls/fonts. The conserved Walker A (light blue), Walker B (pink) and signature C motifs (dark blue) are also highlighted as colored lines. Number labels correspond with the data/labels in Table 1 and Supplementary Table 2 . The residue housing SNPs of pharmacogenomics interest are consistently highlighted by the same colors in Figures 2-4 (Figure 1, Table 1 ). Ile1145 is located in the internal regions of the C-terminal NBD (Figure 2b ). As both isoleucine and valine are non-polar, hydrophobic with neutral side chains, it suggests that preservation of these properties at this site may be important during the evolution of the protein. Similar to the E13/1236C4T, the variability of SNP E27/3435C4T may be influenced at the transcript level or perhaps the methionine 1228 residue, which is observed in S. pombe actually arises due to a mutation at the third nucleotide of the isoleucine codon from ATC to ATG. As is evident from Figure 3c , residue 1145 lies directly adjacent to the highly conserved signature C motif, which is essential for protein function, specifically the binding and hydrolysis of ATP. 32, 33 Despite variation in their level of conservation, and residing in opposing NBDs, the regional conservation scores for these SNPs are highly similar at 56% and 58% for E13/1236C4T and E27/3435C4T, respectively. With the overall regional conservation score 450%, it seems that the region in which these SNPs lie is slightly more conserved than the average of all other SNPs.
It has recently been postulated that the sSNP E27/ 3435C4T (I1145I) (#s20 in Figure 2c ) may alter the tertiary structure of P-gp, and subsequently its stability or expression, when a ribosomal stall occurs during mRNA translation. It is proposed that this ribosomal stall transpires from the presence of a rarer codon and alters the rate of mRNA translation and chaperone-facilitated protein folding. [34] [35] [36] Evidence in support of this hypothesis is, however, limited and the majority of studies focus on the haplotype of this SNP together with SNPs E13/1236C4T (#s6 in Figure 2c ) and E22/2677G4T/A (#ns22 in Figure 2b ), rather than E27/3435C4T (I1145I) (#s20 in Figure 2c ) on its own.
Like E27/3435C4T, E22/2677G4T/A (#ns22 in Figure 2b ) is also more conserved than the average conservation of its immediate surroundings. This non-synonymous SNP confers one of two amino-acid substitutions at position 893 (Ser893Ala/Thr). However, with an individual conservation score of 46% and a regional conservation score of 36%, it seems that both the residue and the region in which it lies may have undergone a degree of variation over the course of evolution (Table 1, Figure 3b ). Residues such as Ala, which is represented at the corresponding position in the ABCB1 homologs of C. l. Familiaris and G. gullus, as well as Cys, which is found in the homologs of D. melanogaster, and Val, which is found in the bacterial homologs Sav1866 and MsbA at amino-acid positions 199 and 203, respectively, (Table 1) all differ from Ser not only in side-chain polarity but also in residue hydropathy index: 1.8, 2.5, 4.2 and À0.8, respectively. 37 To date there have been a vast number of reports correlating the presence of these three SNPs with drug response or disease progression (see Supplementary Table 3) . Some reports highlight individual SNPs as being causative, however, in the majority of cases it is the effect of SNP haplotypes that was assessed. Despite this, evidence for the influence of E13/1236C4T, E22/2677G4T/A and E27/ 3435C4T on various drug pharmacokinetics and response remains controversial. Many contradictory results are reported and as such no definitive conclusion has been presented to explain their influence on drug response. Evidence indicates genetic variation is most prominent at the population level yet many studies fail to state the genetic history of their populations, or present data obtained from cohorts of mixed race (see Supplementary  Table 3 ). There have been reviews that comprehensively covered results from association studies between ABCB1 genotype and protein functions or drug pharmacokinetics. 3, 9, 38 Drawing conclusions from comparisons of many studies is difficult, particularly in assessing the pharmacogenetics of ABCB1. With the availability of the highly homologous mouse 3D crystal structure, we are now able to assess the potential consequences ABCB1 SNPs to protein structure or function. This could assist in the selection of SNPs that are truly functional for future association studies.
The classic E8/554G4T (G185V) polymorphism that influences drug specificity resides in close 3D proximity to two other non-synonymous polymorphisms in a region that is less evolutionary conserved Although research into ABCB1 polymorphisms appears to focus on E13/1236C4T, E22/2677G4T/A and E27/ 3435C4T, it is important to note that a number of additional non-synonymous SNPs have been associated with drug pharmacokinetics, drug response, protein expression and disease progression. In the majority of cases these additional SNPs with established associations can be mapped to the crystal structure of mouse Abcb1a.
One of these SNPs, E8/554G4T (#ns7 in Figure 2b ) confers the classic amino-acid substitution G185V that was reported more than 20 years ago to confer changes in drug specificity of vinblastine and colchicine. 39 This glycine residue was suggested to have a pivotal role in transmitting conformational changes between the catalytic sites and the drug binding sites. 40 Combining molecular dynamics simulations with atomic detail homology modeling, it was further proposed that this improved efflux involves a reduction in non-polar van der Waals forces, which would otherwise secure colchicine to its binding site near or at residue 185. With the substitution of glycine for a more bulky valine residue, such interactions are removed, allowing for improved dissociation and efflux rates. 40, 41 Interestingly, as shown in Figure 4a , in the crystal structure, this SNP resides in close 3D proximity with a molecular distance of 10.9 and 5.2 Å to two other nonsynonymous SNPs, namely E7/431T4C (I144T) (#ns4 in Figure 2b ) and E8/548A4G (N183S) (#ns6 in Figure 2b) , respectively. Nonetheless, as only one of many possible conformations of P-gp is represented in the mammalian Abcb1a crystal structure, 12 there is a possibility that residues that may reside close to one another in one conformation of the 3D structure may not be close together in a different conformation. Hence, we also mapped these SNPs to the ADP-bound half-transporter Sav1866 homolog from Staphylococcus aureus and found that the molecular distances are still similar (11.3 and 5.3 Å ) (Supplementary Figure 2) .
The individual conservation scores are 36, 27 and 45% for I144, N183 and G185, respectively, (Figure 4a , Table 1 ) whereas the average of their regional conservation scores is B40%. In fact, only three residues lying within 10 Å of this SNP cluster possess an individual conservation of greater than 80%. This suggests that some degree of residue variation has been tolerated at this site over the evolution of the protein. It would be interesting to evaluate if these two closeby SNPs also have similar roles in influencing conformational changes between the catalytic sites and the drug binding sites or influence the role of G185V.
The implication of these three SNPs in drug response remains unclear as, to date, none of these SNPs have been investigated and no genotype information is available for these SNPs (Supplementary Table 2 ). It would thus be interesting to determine the frequency of these SNPs as well as their respective haplotypes in the various populations and to determine if drug specificity can be influenced by this cluster of SNPs.
The evolutionary non-conserved E12/1199G4A (S400N), which alters drug pharmacokinetics and response, resides in an evolutionary conserved region SNP E12/1199G4A (S400N) (#ns9 in Figure 2b) , which occurs at o4% in Caucasians and Africans but is not found in Asians (Supplementary Table 2 ) represents another nsSNP that has been associated with drug pharmacokinetics. Through cell-based experiments using limited substrates, Kimchi-Sarfaty et al. 42 inferred that substrate specificity was not significantly influenced by the any of the nonsynonymous coding SNPs including S400N. Nonetheless, using cell-based Quantitative Structure-Activity Relationship (QSAR) analysis, Sakurai et al. 43 concluded that the effect of SNPs on the drug transport activity appears to depend on the substrates tested. Several other studies also revealed that this SNP affects drug pharmacokinetics. Cellular uptake and permeability of five HIV protease inhibitors, especially ritonavir and saquinavir, was increased in cells carrying the minor allele. 44 This SNP was also reported to confer resistance to vinblastine, vincristine, paclitaxel and etoposide, but not doxorubicin. 45, 46 Interestingly, a novel T allele of this SNP (E12/1199G4A (S400N)) coding for the amino acid, isoleucine (I), was identified in 2.3% of leukemia patients. Presence of this novel T allele was found to be associated with reduced resistance to vinblastine, vincristine, paclitaxel and doxorubicin compared with patients carrying the major G allele encoding for serine. On the other hand, patients carrying the more common minor A allele encoding the asparagine amino acid exhibit increased resistance to these drugs compared with those carrying the major G allele. 47 In ovarian cancer patients treated with paclitaxel, the E12/1199G4A/T SNP affected progression-free survival. Although only two patients with heterozygous (G/A) genotype were identified, their mean progression-free survival was only 2 months compared with 19 months for patients who are homozygous for the G allele. 48 From the 3D crystal structure, this polymorphism (S400N) was found to lie in the same turn region between two b-sheets as Gly412, which corresponds to the codon housing the synonymous SNP E13/1236C4T (Figure 4b ) (see flash movie at http://pfs.nus.edu.sg/demo_src/abcb1.html). This SNP resides next to the A-loop (Figures 1 and 4b) , which has previously been identified as being crucial for ATP binding and hydrolysis. 15 The individual evolutionary conservation score for S400 is just 18% indicating it is poorly conserved, and differences in residue properties have been tolerated at this position over the course of evolution (Table 1) . Nonetheless, although serine is present at the corresponding position only in human, canine and mouse, relatively conservative substitution of this residue with other polar residues was observed in all other organisms except for yeast where this residue is substituted with the hydrophobic valine (Table 1) . Interestingly, as depicted in Figure 4b this evolutionary non-conserved residue lies in between two completely conserved residues (conservation scores of 100%) and within a region of high homology where the regional conservation score is 60.7% (Table 1) .
Majority of the other SNPs previously associated with drug pharmacokinetics that could be mapped to the crystal structure reside at the outer surface of the C-terminal NBD Of the eight remaining SNPs to have been associated with drug response or expression, four can be mapped to the mouse Abcb1a crystal structure based on pair-wise alignment (Supplementary Figure 1) . 24, 25 These are E26/3151C4G (P1051A) (#ns25), E27/3322T4C (W1108R) (#ns31), E27/ 3421T4A (S1141T) (#ns33) and E29/3751G4A (V1251I) (#ns36) (Figure 2b ). It is interesting to note that each of these SNPs reside in the C-terminal NBD. These SNPs may have functional significance if they reside at the surface of regions of the protein that are potentially important such as the ATPbinding pockets, or reside in close proximity to such regions. In addition, some parts of the outer surface of the protein may also have a crucial role in the dimerization of the NBDs, either through their impact on ATP binding and hydrolysis, or through the interactions with the opposing NBD.
We highlight the E26/3151C4G (#ns25) SNP, which is translated to P1051A substitution (Figures 2b and 4c ). This substitution is reasonably well conserved and affects only the hydropathy of the protein. Interestingly, this SNP is located at the surface of the C-terminal NBD that forms the ATP-binding pocket. It resides within a turn region between two opposing b-sheets in an almost similar fashion to that of #ns9 E12/1199G4A (S400N) (Figure 4b ), close to the wellconserved A-loop (Tyrosine 1040) and Walker A motif that is crucial for ATP activity. 15, 18 This residue has an individual conservation score of just 18.2% but have a regional conservation score of B60% (Table 1, Figure 4c) suggesting that during the evolution of the protein, there is also considerable tolerance of variation at this residue but not of the surrounding residues. This SNP was found through the yeast-based assay to influence resistance to valinomycin when it is in diplotype with E22/2677G4T/A. 49 Several additional SNPs have been highlighted in some studies for their influence on drug pharmacokinetics, which cannot be mapped to the crystal structure. These are E3/61A4G (N21D), E5/266C4T (M89T), E17/1985T4C (L662R), E17/2005C4T (R669C).
When in haplotype with the intensely studied SNPs E13/1236C4T (#s6), E22/2677G4T/A (#ns22) and E27/3435C4T (#s20), SNP E3/61A4G (N21D), which cannot be mapped to the 3D crystal structure, was reported to increase BODIPY-FL-paclitaxel accumulation and modulate the effect of cyclosporine A on the intracellular accumulation of BODIPY-FL-paclitaxel transport. 50 However, the N21D substitution was found not to influence cyclosporine A pharmacokinetics in another study. 51 In yet another study, the N21D polymorphism was reported to influence the trough but not the peak plasma levels concentration of methadone. 52 Using a yeast-based assay, SNP E27/3421T4A (S1141T) (#ns33) and several SNPs that cannot be mapped to the crystal structure (E5/266C4T (M89T), E17/1985T4C (L662R), E17/2005C4T (R669C)) were reported to increase drug resistance to two or more drugs whereas SNP E27/ 3322T4C (W1108R) (#ns31) decreased drug resistance. 49 Curiously, in another study, the E17/2005C4T (R669C) SNP was reported to be associated with decreased resistance to paclitaxel and etoposide in transfected LLC-PK1 cells. 53 The increased resistance by SNP E17/2005C4T (R669C) was found to be reversed by SNP E27/3322T4C (W1108R) (#ns31). 49 In another study using HEK293T cells, SNP E27/3421T4A (S1141T) (#ns33) was reported to be less sensitive to cyclosporine A inhibition of BODIPY-FL-paclitaxel transport. 50 It was suggested that as the resistance profiles of SNPs E27/3421T4A (S1141T) (#ns33), E27/3322T4C (W1108R) (#ns31) and diplotype E27/3322T4C (W1108R)-E17/ 2005C4T (R669C)) display the largest variation across substrates, the region where S1141T (#ns33) and W1108R (#ns31) reside might contribute to the substrate discrimination activity of P-gp. 49 The 3D crystal structure reveals that both S1141T (#ns33) and W1108R (#ns31) reside at the C-terminal NBD of the P-gp protein with S1141T (#ns33) residing on the outer surface and W1108R (#ns31) residing in the interior of the NBD (Figures 2b, 4d and 4e and flash movie http:// pfs.nus.edu.sg/demo_src/abcb1.html). Interestingly, SNP E27/3421T4A (S1141T) (#ns33) occurs at reasonably high frequency (44%) in the African population but is not found in the non-African populations (Supplementary Table 2 ). It is not a highly conserved residue and does not reside in a highly conserved region of P-gp with an individual conservation score of 45.5 and a regional conservation score of 50.9 (Table 1) . Hence, it is likely that alteration in residue properties at this site was tolerated during the evolution of the protein. No genotype information is available with regards to the other SNP E27/3322T4C (W1108R) (#ns31). This SNP is even less conserved than SNP E27/3421T4A (S1141T) (#ns33) and also less conserved than its immediate surroundings as it has an individual conservation score of only 27.3% and a regional conservation score of 43.5% (Table 1 , Figure 4e ). Hence, these two SNPs, which were speculated to contribute to the substrate discrimination activity of P-gp 49 resides within the C-terminal NBD and are poorly conserved during the evolution of the protein.
SNP E29/3751G4A (V1251I) (#ns36) was found to increase BODIPY-FL-paclitaxel accumulation and modulate the effect of cyclosporine A on the intracellular accumulation of BODIPY-FL-paclitaxel transport. 50 When mapped to the crystal structure, V1251I resides at the outer surface of the C-terminal NBD (Figures 2b and 4f) . Notably, this SNP is highly conserved throughout evolution with an individual score of 81.8% and only conservative changes were observed in 4 of the 11 species examined. Nonetheless, this highly conserved SNP resides in a region that is less conserved (regional conservation score 59.2) suggesting that there is some tolerance of nucleotide changes in the vicinity of this SNP.
Hence, of these several SNPs that had been previously associated with functional differences, most of them (E26/3151C4G (P1051A) (#ns25), E27/3421T4A (S1141T) (#ns33) and E29/3751G4A (V1251I) (#ns36) reside at the outer surface of the C-terminal NBD except for SNP E27/ 3322T4C (W1108R) (#ns31), which resides within the interior of the C-terminal NBD (Table 1, Figure 2b and flash movie http://pfs.nus.edu.sg/demo_src/abcb1.html). Except for SNP E29/3751G4A (V1251I) (#ns36) with high individual conservation score (480%), the other three SNPs have below average conservation scores (o46%). All these SNPs reside within 3D regions that are only moderately conserved throughout evolution (43-60%).
ABCB1 nsSNPs tend to reside in less evolutionary conserved residues Interestingly, there seems to be some correlation between SNPs and the degree of residue conservation. As shown in Supplementary Figure 3A , greater percentage of nsSNPs (up to 12% of nsSNPs versus 7% of sSNPs) has low individual residue conservation score (20-30%) suggesting that nsSNPs tend to reside in less conserved amino acids. However, no clear correlation can be observed between the overall presence of SNPs and the degree of regional conservation score as SNPs are distributed throughout the conserved as well as non-conserved regions of the protein (Supplementary Figure 3B ). Nonetheless, although several SNPs were found to reside close to highly conserved NBD regions, most of the mappable ABCB1 SNPs (39%) are associated with amino acids with low individual and regional conservation scores (Table 1) .
Concluding remarks
In conclusion, of the 66 coding SNPs found in the dbSNP database, B2 synonymous and 12 non-synonymous SNPs have previously been associated with functional differences. Four of these SNPs cannot be mapped to the crystal structure of the protein. Of the remaining 10 previously associated SNPs, which can be mapped to the 3D structure, none reside in the substrate-binding region highlighted by Aller et al.
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Only one SNP, E8/554G4T (G185) (#ns7) resides within the membrane whereas another SNP (E22/2677G4T/A (S893A/ T) (#ns22)) resides in the region between the membrane and the cytosolic N-terminal NBD in the crystal structure, although this residue is part of TM10 (Figure 2 ). The majority of the functionally associated SNPs are localized at the NBD, particularly the external surface of C-terminal NBD suggesting that this domain may have important roles in modulating ABCB1 function. Genotype data that are available for 8 of these 14 previously associated SNPs revealed that the frequencies of these SNPs differed greatly among the various populations examined with SNP E27/ 3421T4A (S1141T) (#ns33) occurring only in the African Americans (Supplementary Table 2 ). Except for synonymous SNP E27/3435C4T (I1145I) (#s20) and non-synonymous SNPs E29/3751G4A (V1251I) (#ns36) and E26/3262G4A (D1088N) (#ns28), these previously associated SNPs have below average individual conservation scores (o46%) and only average regional 31 structure conservation scores (40-60%) suggesting that there is some tolerance of variability in these regions of the P-gp protein, perhaps facilitating differences in substrate specificity of the different polymorphs.
The field of ABCB1 pharmacogenetics has grown considerably in recent years. This is evident both in terms of the number of studies associating ABCB1 polymorphisms with drug pharmacokinetics, and also the number of SNPs being identified in the gene. Despite the increase in association studies there is little clarification on the role ABCB1 SNPs have in drug pharmacokinetics or an individual's response to therapy. Although many studies attempt to investigate the effect of SNPs in ABCB1 on the pharmacokinetics of similar drugs, key differences in their experimental design confound the issue further. Most notably, disparities in study cohorts make comparisons of multiple studies difficult. Inter-individual differences in drug response are most notable between populations of distinct genetic history and therefore true comparisons can only be made between studies assessing patients of known, and equal, genetic history. This is rarely achievable and remains a factor that must be addressed in future studies.
As more SNPs are identified through the current state-ofthe-art Next Generation Sequencing technologies, it is pertinent to understand how changes in the sequences of genes will impact the structure, and ultimately the function, of the proteins these genes encode. Depicting the location of residues corresponding to non-synonymous, as well as synonymous SNPs, and their evolutionary conservation, in the 3D crystal structure of mammalian P-gp provides a more realistic and accurate method of SNP visualization than the more common 2D schematic diagrams. This review highlights the feasibility of such visualization methods, which may be extended for use in the interpretation of results from current association studies, and in allowing for an improved method of selection of exonic SNPs for functional validation assays.
